Experienced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome

Dr. Zujun Li

Oncology | Hematology
New York University
111 Broadway, 
New York, NY 
 (411.8 mi)
Experienced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
New York University
111 Broadway, 
New York, NY 
 (411.8 mi)
OverviewInsuranceLocationsClinical Research

Overview

Zujun Li is an Oncologist and a Hematologist in New York, New York. Dr. Li and is rated as an Experienced provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Laryngeal Cancer, Throat Cancer, Glioma, and Colorectal Cancer.

His clinical research consists of co-authoring 29 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
Nyu Langone Hospitals
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

NEW YORK UNIVERSITY
111 Broadway, New York, NY 10006
Other Locations
NEW YORK UNIVERSITY
530 1st Ave, New York, NY 10016
NEW YORK UNIVERSITY
160 E 34th St, New York, NY 10016

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Terminated
Publish Date: January 27, 2025
Intervention Type: Drug, Procedure, Diagnostic test, Radiation
Study Drug: Birinapant
Study Phase: Phase 1
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
Enrollment Status: Completed
Publish Date: February 10, 2022
Intervention Type: Drug
Study Drug: PDR001
Study Phase: Phase 2
View 4 Less Clinical Trials

29 Total Publications

A Preliminary Validation of an Optimal Cutpoint in Total Number of Patient-Reported Symptoms in Head and Neck Cancer for Effective Alignment of Clinical Resources with Patients' Symptom Burden.
A Preliminary Validation of an Optimal Cutpoint in Total Number of Patient-Reported Symptoms in Head and Neck Cancer for Effective Alignment of Clinical Resources with Patients' Symptom Burden.
Journal: Cancer care research online
Published: April 08, 2024
Similar Doctors
Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Gerardo Capo
Hematology | Oncology
Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Gerardo Capo
Hematology | Oncology

Barnabas Health Medical Group PC

225 Williamson St, 
Elizabeth, NJ 
 (11.1 mi)
888-724-7123
Languages Spoken:
English
See accepted insurances

Gerardo Capo is a Hematologist and an Oncologist in Elizabeth, New Jersey. Dr. Capo and is rated as an Advanced provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Stomach Cancer, Alpha Thalassemia X-Linked Intellectual Disability Syndrome, Alpha Thalassemia, Colorectal Cancer, and Liver Embolization.

Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Francisco A. Garcia-Moreno
Hematology Oncology | Hematology | Oncology
Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Francisco A. Garcia-Moreno
Hematology Oncology | Hematology | Oncology

Optum Medical Care PC

90 S Bedford Rd, 
Mount Kisco, NY 
 (37.0 mi)
914-241-1050
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Francisco Garcia-Moreno is a Hematologist Oncology specialist and a Hematologist in Mount Kisco, New York. Dr. Garcia-Moreno and is rated as an Advanced provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Alpha Thalassemia, Alpha Thalassemia X-Linked Intellectual Disability Syndrome, Thalassemia, and Iron Deficiency Anemia.

Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Tibor Moskovits
Hematology Oncology | Hematology
Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Dr. Tibor Moskovits
Hematology Oncology | Hematology

New York University

530 1st Ave, 
New York, NY 
 (3.0 mi)
212-263-7300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tibor Moskovits is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Moskovits and is rated as a Distinguished provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, Anal Cancer, Essential Thrombocythemia, and Bone Marrow Aspiration.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile